For instance, in PD models, C/EBPβ reduction has been shown to mitigate dopaminergic neuronal damage and glial activation, suggesting that C/EBPβ depletion could be a valuable therapeutic target for PD (52). This evidence concerns the gene CEBPB and Parkinson disease.